PARP1 and acute myeloid leukemia: Patients with M4/M5 AML with the lowest expression of PARP1 (0%–66%) exhibited a 50% improved overall survival (OS) rate (HR = 0.66, p = 0.016) as compared with the highest expressing (66%–100%) group (Figure 5B).